FDA Wants Your Take on Gluten Labels: Celiac Cross-Contact Crackdown?
Published Date: 1/22/2026
Notice
Summary
The FDA is asking for your thoughts on a petition to make gluten labeling clearer and to prevent accidental gluten contamination in packaged foods. This affects food makers and people with celiac disease who need safer, easier-to-understand labels. Comments are open until March 23, 2026, so jump in now to help shape safer gluten rules without extra costs yet.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 1 costs, 2 mixed.
Proposal to Name All Gluten Ingredients
A citizen petition asks FDA to require that every ingredient that contains gluten be listed by name in the ingredient list (e.g., explicitly naming rye, barley, oats). FDA has published a request for information and is seeking comments by March 23, 2026. This change would make it easier for people with celiac disease or other gluten-related conditions to identify unsafe products.
Request to Add Gluten to CPG Allergen List
Celiac Journey asked FDA to add gluten to the list of allergens in Compliance Policy Guide (CPG) Sec. 555.250 to address labeling and cross-contact. FDA is considering the petition as it finalizes a draft update to Sec. 555.250, which, if finalized, would replace the existing guidance and could change enforcement policy about allergen disclosure and controls.
Oats and Cross-Contact Under Review
The petition asks FDA to consider oats as a gluten-containing grain because oats can contain gluten from cross-contact; FDA requests data on how often oats contain gluten, amounts present, labeling practices (e.g., "may contain"), and the prevalence/severity of reactions. Any future decision could change labeling or handling of oat-containing products.
Possible Manufacturing Cross-Contact Controls
The petition asks FDA to require controls to prevent cross-contact with gluten-containing grains during food manufacturing. If adopted, food makers may need to adopt or expand preventive controls, sanitation, or segregation practices to avoid gluten cross-contact.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-01120 — Self-Regulatory Organizations; The Nasdaq Stock Market LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend the Pricing Schedule for Exchange-Traded Products To Add Class ETF Shares, Eliminate Prorated Refunds for Liquidations, and Make Modifications to the Designated Liquidity Provider and Market Quality Supporter Incentive Programs
Nasdaq is updating its fees and rules for Exchange-Traded Products (ETPs). They’re adding a new Class ETF Shares fee, stopping partial refunds when ETPs close, and tweaking how they reward market makers who keep trading smooth. These changes kick in right away and could affect anyone listing or trading these products on Nasdaq.
Next: 2026-01122 — Arms Sales Notification
The U.S. is updating its arms sales to India by adding more support and parts for their C-17 aircraft fleet. This boosts the total deal value from $670 million to $800 million, focusing on non-major equipment upgrades and sustainment. These changes keep India’s Air Force flying strong with better maintenance and training, with no new big weapons involved.